Use access key #2 to skip to page content.
  • S&P 500: 1,089.27
  • Change: -0.20%
$9.18 -0.22 (-2.29%)
11/30/2009 2:04 PM

Seattle Genetics, Inc. (SGEN)

CAPS Rating:
****

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating SGEN

Add Stock to Watchlist

What the Community Thinks

Total Members

273 Outperforms
21 Underperforms
 

All-Stars

55 Outperforms
8 Underperforms
 

Wall Street

10 Outperforms
1 Underperforms
 

Members bullish on SGEN are also bullish on:

Members bearish on SGEN are also bearish on:

Ticker Tags

Small Cap (1619), Rule Breakers Universe (128), Healthcare (732), Growth (1897), Aggressive Growth (873), Defensive (1498), Biotechnology (225)
Suggest a tag

Seattle Genetics, Inc. At A Glance

Current Price: $9.18
Last Trade Time: 11/30/2009 2:04 PM
Open: $9.26
Previous Close: $9.39
Daily Range: $9.05 - $9.39
52-Week Range: $7.00 - $14.94
Volume: 808,621
Market Cap: $922.38M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

SGEN VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Seattle Genetics, Inc. (SGEN)

Avatar TMFBreakerBrian (99.34) Submitted: 3/31/08 1:36 PM

Biopharmaceuticals are being valued at a premium and Seattle Genetics has the goods. Is it the blood cancer biologics version of solid tumor small molecule Exelixis?

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Seattle Genetics, Inc. (SGEN)

Avatar georicheck (37.31) Submitted: 8/03/07 11:48 AM

Needs a product to succeed.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 45 :   1 2 3 4 5 Next »

Recs

0

 (SGEN)

Avatar dcsccr (< 20) Submitted: 7/10/09 11:53 AM : Outperform Start Price: $8.87 SGEN Score: -21.69

antibodies and their conjugates are the future of cancer therapeutics

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar gokylego (59.79) Submitted: 4/28/09 11:01 PM : Outperform Start Price: $8.98 SGEN Score: -25.65

Partnered well with funding and a intriguing pipeline.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar SpaceMonkey01 (82.06) Submitted: 3/29/09 12:28 PM : Outperform Start Price: $9.61 SGEN Score: -43.21

Moving Average Convergence/Divergence (MACD) indicates a Bullish Trend.
Chart pattern indicates a Strong Upward Trend.
Relative Strength is Bullish.
Up/Down volume pattern indicates that the stock is under Accumulation.
The 50 day Moving Average is rising which is Bullish.
The 200 day Moving Average is rising which is Bullish.
Look for Support at 9.89
Watch for resistance at 10.84

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar Chooseandhold (36.99) Submitted: 11/08/08 2:43 PM : Outperform Start Price: $10.89 SGEN Score: -33.73

Great biotech with a great pipeline and money

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar RNZ100 (80.94) Submitted: 10/08/08 8:28 PM : Outperform Start Price: $8.79 SGEN Score: -8.31

Oversold (but then again, what isn't?!)

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 45 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 11 of 11  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJimCramer 59.77 11/04/09 Underperform 3W $8.95+2.60%+4.37%+1.76
TrackDeutscheSec 84.93 08/13/09 Outperform NS $11.25-18.37%+10.51%-28.88
TrackOppenheimer < 20 10/27/08 Outperform NS $8.28+10.91%+29.88%-18.98
TrackRBCCapMkts 82.27 03/19/08 Outperform NS $8.63+6.41%-14.93%+21.34
TrackMichaelBrus 89.98 02/14/08 Outperform 1Y $9.35-1.79%-15.57%+13.79
TrackJPMorgan 64.79 01/28/08 Outperform NS $9.34-1.68%-14.37%+12.69
TrackFortisBank 82.13 09/21/07 Outperform NS $11.79-22.11%-24.87%+2.76
TrackWMBlair < 20 08/21/07 Outperform NS $11.03-16.75%-20.32%+3.58
TrackBofASec 91.59 12/12/06 Outperform NS $6.17+48.83%-17.97%+66.81
TrackNeedham < 20 10/25/06 Outperform NS $4.92+86.65%-15.65%+102.30
TrackNextGen 49.48 10/06/06 Outperform NS $4.95+85.52%-13.83%+99.34

Results 1 - 11 of 11  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD02 0ms